MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

Slides:

Advertisements

Similar presentations

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Advertisements

PI 3-kinase inhibition has no effect on ANG II induced extracellular recognition kinase (ERK) 1/2 activation. PI 3-kinase inhibition has no effect on ANG.

A: inhibition of the erbB2 receptor abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the.

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

by Thomas T. Murooka, Ramtin Rahbar, Leonidas C

MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination in cells.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Phosphatidylinositol 3-Kinase/Akt-Dependent and -Independent Protection Against Apoptosis in Normal Human Melanocytes Masahiro Oka, Akiko Kageyama, Mizuho.

Volume 19, Issue 1, Pages (January 2011)

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

AKT dependence of ovarian cancer cell lines.

PDK1 regulates PLK1 in vivo and in vitro.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

Phospho-Twist1–induced TGF-β2 acts as an essential mediator of signaling cross-talk between TGF-βR/Smad2 and PI3K/Akt axes. Phospho-Twist1–induced TGF-β2.

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

Volume 27, Issue 1, Pages (January 2015)

Volume 27, Issue 1, Pages (January 2015)

NM-3 induces p21 levels and down-regulation of Cdk2 activity.

MPG is a substrate of ATM, and phosphorylation of MPG is essential for function. MPG is a substrate of ATM, and phosphorylation of MPG is essential for.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Leto et al., Supplementary Figure S3

AKT2, but not AKT1, is required for regulating survival of PTEN-deficient prostate tumor spheroids. AKT2, but not AKT1, is required for regulating survival.

Validation of FGFR1 and PLXDC2 as BACE2 substrates in COS-1 overexpression system. Validation of FGFR1 and PLXDC2 as BACE2 substrates in COS-1 overexpression.

mTORC1- and mTORC2-activating mutations in MTOR and RHEB

AMPK directly increases mTORC2 catalytic activity.

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Wrch-1 binds to the regulatory p85 subunit of PI3K and is necessary for Akt activation. Wrch-1 binds to the regulatory p85 subunit of PI3K and is necessary.

PKIs block DHT + bombesin-induced transactivation of probasin ARR3 tk-luc and PSA pPUE-E1b-Luc report constructs. PKIs block DHT + bombesin-induced transactivation.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Class 1 phosphatidylinositol 3-kinase (PI3K) p85 subunit dominant negative adenovirus regulates Pax2 and GAPDH abundance in NRK-52E cells. Class 1 phosphatidylinositol.

The dynamics of Akt activation in cultured human keratinocytes.

Curcumin-generated ROS activates Chk1 and Chk2 kinases.

PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.

Identification of NSC as a FADD-kinase inhibitor.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

Overexpression of Pim kinases contributes to increased protein translation in resistant cells through controlling cap-independent translation. Overexpression.

Sensor siRNAs can be used in high-order combinations.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

Role of MAPKs on DPP-23-induced autophagy and apoptosis.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

ERK reactivation following EGFR TKI treatment.

ABT-100 inhibits PI3K activity and p85 tyrosine phosphorylation.

IGF-I partially protects Rh30 cells from apoptosis despite simultaneous inhibition of PI3K-Akt and MAP kinase pathways. IGF-I partially protects Rh30 cells.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

Combined inhibition of coamplified RTKs is required for response.

The effects of AZD1775 and olaparib on DNA damage response signaling.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

Quercetin induces autophagy, blocks cell cycle and activation of ERK and JNK signaling pathways participates in the G1 arrest in P39 cells. Quercetin induces.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase 3 cleavage and U937 cytotoxicity. Afatinib rapidly destabilizes endogenous.

I3C reduces the level of Cdc25A protein in breast cancer cells.

MEK1/2-ERK1/2-p190RHOGAP and INK4a/ARF deficiency drive RHOA activation in NSCLC. A and B, G-LISA assay showing RHOA-GTP levels in H460, A549, and H838.

KDM4A levels affect the distribution of translation initiation factors

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

mTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. A, BT-474 cells were treated with 500 nM of AZD8055 and collected at the indicated times, and lysates were immunoblotted with indicated antibodies (panel 1 is the same as Fig. 2A, panel 1). After 8 hours of AZD8055 treatment, the cells were treated with either 1 μM of PI-103 (panel 2), or 200 nM of lapatinib (panel 3 in A). Each inhibitor was added for 1 extra hour (indicated as time 9), 4 extra hours (indicated as time 12), or 16 extra hours (indicated as time 24), and the lysates were immunoblotted with the indicated antibodies (see also Supplementary Fig. S4). B, BT-474 cells were treated simultaneously with both 500 nM of AZD8055 and 1 μM of lapatinib and were collected at the indicated times, and lysates immunoblotted with indicated antibodies. Vanessa S. Rodrik-Outmezguine et al. Cancer Discovery 2011;1:248-259 ©2011 by American Association for Cancer Research